Holen Sie sich die Stockscreener-App
29.84
1.95%
0.6185
Schlusskurs vom Vortag:
$29.22
Offen:
$29.45
24-Stunden-Volumen:
1.15M
Relative Volume:
1.70
Marktkapitalisierung:
$1.96B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-137.95M
KGV:
-11.83
EPS:
-2.5226
Netto-Cashflow:
$-107.11M
1W Leistung:
+0.34%
1M Leistung:
+48.95%
6M Leistung:
+73.50%
1J Leistung:
+230.63%
1-Tages-Spanne:
$29.06
$30.99
1-Wochen-Bereich:
$28.62
$30.99
52-Wochen-Spanne:
$8.98
$30.99
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Firmenname
Bicara Therapeutics Inc
Sektor
Branche
Telefon
617-468-4219
Adresse
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
29.79 | 1.91B | 0 | -137.95M | -107.11M | -2.5226 |
VRTX
Vertex Pharmaceuticals Inc
|
524.31 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.45 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.42 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.25 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.81 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-25 | Eingeleitet | BofA Securities | Buy |
| 2026-01-29 | Eingeleitet | Citizens JMP | Mkt Perform |
| 2026-01-08 | Eingeleitet | BTIG Research | Buy |
| 2025-12-18 | Eingeleitet | Mizuho | Neutral |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-05-23 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Eingeleitet | Wells Fargo | Underweight |
| 2025-02-06 | Eingeleitet | Wedbush | Outperform |
| 2024-12-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
| 2024-10-08 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten
Bicara Therapeutics Inc stock hits all-time high at 29.92 USD - Investing.com Canada
Price to earnings forward of Bicara Therapeutics Inc. – NASDAQ:BCAX - TradingView
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Citizens upgrades Bicara Therapeutics stock price target on CRC data - Investing.com UK
Citizens upgrades Bicara Therapeutics stock price target on CRC data By Investing.com - Investing.com South Africa
BICARA THERAPEUTICS INC (BCAX) Stock Chart - ChartMill
Bicara Therapeutics stock hits 52-week high at 27.98 USD - Investing.com
Bicara Therapeutics stock hits 52-week high at 27.98 USD By Investing.com - Investing.com Australia
BCAXBicara Therapeutics Inc Volatility & Greeks - Finviz
Bicara Therapeutics Inc. Actuals & Estimates (BOATS:BCAX) - TradingView
Bicara Therapeutics Inc. Actuals & Estimates (NASDAQ:BCAX) - TradingView
Form 144 BICARA THERAPEUTICS INC. For: 25 June By Investing.com - Investing.com Nigeria
BCAX (NASDAQ: BCAX) affiliate to offer 50,000 shares after option exercise - Stock Titan
BCAX Forecast — Price Target — Prediction for 2027 - TradingView
Bicara Therapeutics Inc (BCAX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bicara Therapeutics stock hits 52-week high at 24.29 USD - Investing.com
Bicara Therapeutics stock hits 52-week high at 24.29 USD By Investing.com - Investing.com South Africa
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? - AOL.com
Bicara Therapeutics Inc (BCAX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bicara Therapeutics Inc (BCAX) Institutional Confidence - TradingKey
Bicara Therapeutics Inc (BCAX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bicara Therapeutics Inc (BCAX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bicara Therapeutics Inc (BCAX) Valuation: PE, PB & Fair Value Analysis - TradingKey
[Bicara Therapeutics (BCAX) Rises 1.35% as Stock Holds Above Key SupportTICK Divergence - Město Břeclav
Bicara Therapeutics Inc (BCAX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bicara Therapeutics Inc (BCAX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bicara Therapeutics Inc (BCAX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bicara Therapeutics Inc. appoints Chris Sarchi as Chief Commercial Officer to drive commercial growth - Traders Union
Bicara Therapeutics CEO Sells 15,000 Shares: Insider Transaction Under ScrutinyDividend Earnings Report - newsline.com
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? - The Motley Fool
Bicara Therapeutics Inc. joins ACS CAN in efforts to shape evidence-based cancer policies - Traders Union
Bicara Therapeutics Holds 2026 Annual Stockholder Meeting - TipRanks
[Form 4] Bicara Therapeutics Inc. Insider Trading Activity - Stock Titan
Bicara Therapeutics (BCAX) director receives 19,475-share option tied to RA Capital - Stock Titan
[8-K] Bicara Therapeutics Inc. Reports Material Event - Stock Titan
Bicara Therapeutics Inc. presents three year Phase 1b results for ficerafusp alfa combination in HPV negative HNSCC - Traders Union
BCAX Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Clinical Pipeline ProgressDebt Analysis Report - newsline.com
Bicara Therapeutics (BCAX) Edges Lower, Tests Key Support LevelsCumulative Volume - newsline.com
BCAX Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Pre‑Revenue Biotech’s R&D SpendingFinancial Data - newsline.com
Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Cantor Fitzgerald reiterates Bicara Therapeutics stock rating - Investing.com
Cantor Fitzgerald reiterates Bicara Therapeutics stock rating By Investing.com - Investing.com India
Bicara (BCAX) Q4 2025 Earnings Transcript - AOL.com
Finanzdaten der Bicara Therapeutics Inc-Aktie (BCAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.18%
2.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):